ALT
Altimmune, Inc. NASDAQ Listed May 26, 2017$3.04
After hrs
$3.07
-0.65%
Mkt Cap $268.3M
52w Low $2.56
9.3% of range
52w High $7.73
50d MA $3.41
200d MA $4.02
P/E (TTM)
-2.8x
EV/EBITDA
-3.3x
P/B
1.1x
Debt/Equity
0.2x
ROE
-39.2%
P/FCF
-4.7x
RSI (14)
—
ATR (14)
—
Beta
0.34
50d MA
$3.41
200d MA
$4.02
Avg Volume
4.1M
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
910 Clopper Road · Gaithersburg, MD 20878 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 5, 2026 | AMC | -0.25 | -0.27 | -8.0% | 3.51 | +0.9% | +0.9% | +10.5% | +10.0% | +8.3% | +2.6% | — |
| Nov 6, 2025 | AMC | -0.29 | -0.21 | +27.6% | 3.94 | -0.5% | +4.3% | +8.1% | +8.6% | +7.4% | +3.0% | — |
| Aug 12, 2025 | AMC | -0.32 | -0.27 | +15.6% | 3.62 | +0.6% | +3.3% | +1.7% | +0.3% | -1.7% | +0.0% | — |
| May 13, 2025 | AMC | -0.35 | -0.26 | +25.7% | 5.76 | +0.5% | -1.0% | +0.3% | -3.1% | -4.5% | +1.6% | — |
| Feb 27, 2025 | AMC | -0.34 | -0.33 | +2.9% | 6.42 | -2.6% | +3.6% | -6.7% | -7.2% | -10.9% | -12.9% | — |
| Nov 12, 2024 | AMC | -0.36 | -0.32 | +11.1% | 9.49 | +2.7% | +0.3% | -10.9% | -19.8% | -24.7% | -21.3% | — |
| Aug 8, 2024 | AMC | -0.34 | -0.35 | -2.9% | 6.33 | +1.1% | -2.5% | -1.7% | -0.3% | -2.4% | -1.4% | — |
| May 9, 2024 | AMC | -0.36 | -0.34 | +5.6% | 7.72 | -0.9% | -6.5% | -4.5% | +1.3% | +14.9% | +15.3% | — |
| Mar 27, 2024 | AMC | -0.35 | -0.33 | +5.7% | 8.89 | +1.9% | +14.5% | +15.1% | +5.3% | +4.5% | +0.1% | — |
| Nov 7, 2023 | AMC | -0.40 | -0.39 | +2.5% | 2.70 | -0.4% | +0.0% | -9.3% | -7.4% | -9.6% | -10.7% | — |
| Aug 10, 2023 | AMC | -0.44 | -0.32 | +27.3% | 3.04 | +0.3% | -1.0% | -2.0% | -7.6% | -10.5% | -11.5% | — |
| May 11, 2023 | AMC | -0.49 | -0.40 | +18.4% | 5.33 | +1.1% | -4.5% | -9.0% | -12.8% | -13.7% | -16.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 24 | Goldman Sachs | Upgrade | Sell → Neutral | $2 | $2.89 | $2.95 | +2.1% | -1.4% | -3.1% | -5.2% | -9.0% | -10.0% |
| Mar 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.50 | $3.60 | +2.9% | +3.4% | +0.9% | -2.3% | -2.3% | -4.6% |
| Mar 6 | B. Riley Securities | Maintains | Buy → Buy | — | $3.51 | $3.54 | +0.9% | +0.9% | +10.5% | +10.0% | +8.3% | +2.6% |
| Nov 7 | Citizens | Maintains | Market Outperform → Market Outperform | — | $3.94 | $3.92 | -0.5% | +4.3% | +8.1% | +8.6% | +7.4% | +3.0% |
| Oct 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.83 | $3.87 | +1.0% | +4.4% | +5.5% | +1.8% | +3.4% | +3.1% |
| Oct 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.00 | $4.03 | +0.8% | -2.0% | +0.0% | -0.8% | +0.0% | -2.8% |
| Aug 13 | UBS | Maintains | Buy → Buy | — | $3.62 | $3.64 | +0.6% | +3.3% | +1.7% | +0.3% | -1.7% | +0.0% |
| Aug 13 | B. Riley Securities | Maintains | Buy → Buy | — | $3.62 | $3.64 | +0.6% | +3.3% | +1.7% | +0.3% | -1.7% | +0.0% |
| Aug 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.62 | $3.64 | +0.6% | +3.3% | +1.7% | +0.3% | -1.7% | +0.0% |
| Jul 10 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $4.74 | $4.00 | -15.6% | -7.2% | -12.7% | -10.1% | -11.8% | -11.8% |
| Jun 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.61 | $3.64 | +0.8% | -3.0% | +7.2% | +17.2% | +35.7% | +31.9% |
| Apr 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.78 | $4.48 | -6.3% | -6.7% | -11.3% | -16.7% | -23.2% | -11.5% |
| Apr 2 | Citizens Capital Markets | Maintains | Market Outperform → Market Outperform | — | $4.75 | $4.67 | -1.7% | +0.6% | -6.1% | -10.7% | -16.2% | -22.7% |
| Mar 14 | Citizens Capital Markets | Maintains | Market Outperform → Market Outperform | — | $5.20 | $5.39 | +3.7% | +13.8% | +14.8% | +7.9% | +11.7% | +11.2% |
| Mar 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.65 | $6.71 | +0.9% | -9.9% | -10.4% | -14.0% | -15.9% | -16.2% |
| Feb 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.64 | $6.70 | +0.9% | +5.3% | +4.1% | +0.3% | -0.5% | -5.3% |
| Jan 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.94 | $6.86 | -1.2% | +1.7% | +0.6% | +0.9% | -0.1% | +0.1% |
| Jan 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.83 | $6.81 | -0.3% | +1.6% | +3.4% | +2.2% | +2.5% | +1.5% |
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.52 | $9.55 | +0.3% | -11.1% | -20.1% | -24.9% | -21.5% | -15.4% |
| Aug 12 | B. Riley Securities | Maintains | Buy → Buy | — | $6.17 | $6.17 | +0.0% | +0.8% | +2.3% | +0.2% | +1.1% | +5.2% |
| Jun 25 | B. Riley Securities | Maintains | Buy → Buy | — | $7.14 | $7.11 | -0.4% | +3.8% | -12.3% | -10.5% | -6.9% | +0.8% |
| Jun 21 | Piper Sandler | Maintains | Overweight → Overweight | — | $5.94 | $6.00 | +1.0% | +7.9% | +20.2% | +24.7% | +5.4% | +7.6% |
| May 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.37 | $7.53 | +2.2% | +6.1% | +20.4% | +20.8% | +8.7% | +9.1% |
| May 10 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $7.72 | $7.65 | -0.9% | -6.5% | -4.5% | +1.3% | +14.9% | +15.3% |
| Apr 29 | Guggenheim | Downgrade | Buy → Neutral | — | $7.26 | $6.86 | -5.5% | -11.8% | -9.8% | -2.6% | -1.0% | +0.6% |
| Apr 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.18 | $10.25 | +0.7% | +0.5% | -8.1% | -8.7% | -12.6% | -10.7% |
| Mar 28 | B. Riley Securities | Maintains | Buy → Buy | — | $8.89 | $9.06 | +1.9% | +14.5% | +15.1% | +5.3% | +4.5% | +0.1% |
| Feb 13 | B. Riley Securities | Maintains | Buy → Buy | — | $10.40 | $9.88 | -5.0% | -18.7% | -13.4% | -13.9% | -15.8% | -19.2% |
| Dec 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.16 | $5.74 | +81.6% | +13.0% | +46.5% | +63.6% | +117.7% | +108.2% |
| Nov 9 | B. Riley Securities | Maintains | Buy → Buy | — | $2.70 | $2.71 | +0.4% | -9.3% | -7.4% | -9.6% | -10.7% | -9.6% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.01 | $3.01 | +0.0% | -1.0% | -6.6% | -9.6% | -10.6% | -12.0% |
| Aug 11 | B. Riley Securities | Maintains | Buy → Buy | — | $3.04 | $3.05 | +0.3% | -1.0% | -2.0% | -7.6% | -10.5% | -11.5% |
| Jul 12 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $3.38 | $3.43 | +1.5% | -1.8% | +0.3% | -3.0% | -5.9% | -6.8% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.09 | $5.15 | +1.2% | -4.7% | -8.6% | -9.6% | -12.6% | -11.8% |
| Mar 31 | JMP Securities | Maintains | Market Outperform → Outperform | — | $4.22 | $4.21 | -0.2% | +0.0% | +4.7% | -2.4% | -8.3% | -5.0% |
| Mar 22 | JMP Securities | Maintains | Market Outperform → Outperform | — | $4.95 | $4.99 | +0.8% | -15.2% | -15.4% | -12.7% | -2.6% | -10.7% |
| Mar 22 | Goldman Sachs | Downgrade | Buy → Neutral | — | $4.95 | $4.99 | +0.8% | -15.2% | -15.4% | -12.7% | -2.6% | -10.7% |
| Mar 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.05 | $11.08 | +0.3% | +2.9% | -6.2% | -2.4% | +0.4% | -1.1% |
| Feb 6 | JMP Securities | Maintains | Market Outperform → Outperform | — | $15.16 | $15.10 | -0.4% | +0.5% | +0.1% | -8.6% | -7.5% | -11.4% |
| Jan 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.96 | $14.96 | +0.0% | -4.1% | -2.6% | -5.3% | -6.2% | -7.0% |
| Jan 18 | Evercore ISI | Maintains | Outperform → Outperform | — | $14.96 | $15.26 | +2.0% | +0.1% | +0.0% | -4.1% | -2.6% | -5.3% |
| Dec 1 | Goldman Sachs | Maintains | Buy → Buy | — | $9.95 | $10.80 | +8.5% | +8.4% | +13.4% | +11.2% | +3.5% | +2.8% |
| Nov 11 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $10.58 | $10.35 | -2.2% | +1.0% | +0.1% | +3.2% | -9.8% | -16.9% |
| Sep 16 | Guggenheim | Maintains | Buy → Buy | — | $14.39 | $14.22 | -1.2% | -5.0% | -10.9% | -12.4% | -11.8% | -7.2% |
| Aug 31 | Jefferies | Maintains | Buy → Buy | — | $18.94 | $19.20 | +1.4% | +16.6% | +15.3% | +18.3% | +11.5% | +6.9% |
| Aug 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.66 | $17.87 | +1.2% | -2.7% | +2.5% | -2.8% | +0.2% | +4.4% |
| Aug 12 | B. Riley Securities | Maintains | Buy → Buy | — | $13.77 | $13.80 | +0.2% | +26.1% | +27.4% | +28.2% | +24.8% | +31.4% |
| May 18 | Piper Sandler | Maintains | Overweight → Overweight | — | $5.29 | $5.13 | -3.0% | -8.5% | -8.9% | -5.1% | -8.3% | -10.8% |
| Jun 30 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $15.90 | $10.71 | -32.6% | -38.1% | -36.9% | -41.3% | -44.2% | -47.0% |
| Jun 30 | B. Riley Securities | Maintains | Buy → Buy | — | $15.90 | $10.71 | -32.6% | -38.1% | -36.9% | -41.3% | -44.2% | -47.0% |
No insider trades available.
8-K
Altimmune, Inc. -- 8-K Filing
Altimmune's capital raise will fund its Phase 3 trial for pemvidutide in MASH and pre-commercial activities, providing runway to advance its lead metabolic disease program.
Apr 24
8-K · 5.03
! Medium
Unknown — 8-K 5.03: Amendment to Articles / Bylaws
Altimmune increased authorized shares, enabling potential dilution for future fundraising or acquisitions, which could pressure existing shareholders' ownership percentages and earnings per share.
Apr 16
8-K
Altimmune, Inc. -- 8-K Filing
Altimmune reports full-year 2025 results and reaffirms its late-stage development focus on pemvidutide for metabolic dysfunction-associated fatty liver disease, positioning the candidate as a differentiated treatment option for serious liver conditions.
Mar 5
8-K · 8.01
!! High
Altimmune, Inc. -- 8-K 8.01: Material Event / Announcement
Altimmune scheduled its 2026 Annual Meeting for April 16, 2026, with a March 13 record date, allowing shareholders to vote on corporate matters.
Feb 3
Data updated apr 24, 2026 5:32pm
· Source: massive.com